Introduction:
Biosimilar Reference Standard Characterization is the systematic analytical profiling that establishes the properties of reference materials used to evaluate product quality, consistency and similarity to an approved reference biologic. A scientifically characterized reference standard helps manufacturers generate reliable analytical data throughout development, manufacturing and quality control.
Biosimilars are biological medicines shown to be highly similar to an approved reference product, with no clinically meaningful differences in safety, purity and potency. Because biologics are large, complex molecules produced in living systems, quality assessment needs far more than a single purity test or molecular weight measurement. Differences in glycosylation, higher-order structure, charge variants, aggregation or biological activity can influence product quality and must be evaluated with suitable methods.
Reference standard development gives these assessments a structured foundation. The process includes selecting an appropriate material, establishing its molecular and physicochemical attributes, evaluating biological activity where applicable and documenting its suitability for each intended use.
At ResolveMass Laboratories Inc., our scientists support biosimilar developers with high-resolution mass spectrometry and orthogonal analytical programs, backed by documentation designed for regulatory review. This guide explains the service, the attributes and techniques that matter, how the work connects to regulatory expectations and clinical strategy, and what to look for in an analytical partner.
Summary:
- What it is: Biosimilar reference standard characterization establishes the identity, purity, potency and critical quality attributes (CQAs) of the reference materials used in biosimilar development and quality control.
- Why it matters: Well-characterized standards support method development, qualification, validation, comparability studies, stability testing and batch release.
- How it is done: Orthogonal techniques such as LC-MS, peptide mapping, SEC, CE-SDS, HPLC, icIEF, glycan profiling and functional assays build a complete molecular quality profile.
- How it is developed: Material selection, homogeneity assessment, stability monitoring, documented characterization and controlled storage.
- Regulatory alignment: Developers must show analytical similarity to the reference biologic through a risk-based, scientifically justified approach consistent with ICH, FDA, EMA, WHO and Health Canada guidance.
- Bigger picture: Strong analytical data also influence the extent of clinical work needed, including PK/PD studies, biomarkers and how residual uncertainty is addressed.
- Why ResolveMass: A Canadian analytical CRO/CDMO with deep mass spectrometry and biosimilar characterization expertise and a documentation-first approach.
1: What Is Biosimilar Reference Standard Characterization?
Biosimilar reference standard characterization is the systematic evaluation of a reference material’s identity, purity, structural attributes, biological activity and stability to establish its suitability for specific analytical and quality-control purposes.
A reference standard may be an approved reference product, a qualified in-house reference material or another appropriately established material, depending on intended use. These materials are not automatically interchangeable. Suitability depends on the analytical question, the qualification strategy and the applicable regulatory requirements.
| Term | Meaning | Typical use |
|---|---|---|
| Reference product | The licensed innovator biologic the biosimilar is compared against | Biosimilarity and comparability exercises |
| Primary reference standard | A highly characterized lot that anchors other standards | Qualification of secondary standards |
| Secondary (working) standard | A lot qualified against the primary standard | Routine release, stability and system suitability |
| In-house reference standard | A developer-owned standard qualified for a specific product | Assay calibration and lot comparison |
Main objectives of Biosimilar Reference Standard Characterization
- Confirm molecular identity and relevant structural features
- Establish purity and impurity profiles
- Assess critical quality attributes (CQAs)
- Support analytical method development and validation
- Provide a consistent comparator for product characterization
- Monitor changes during storage and repeated use
- Generate traceable documentation for quality and regulatory review
A well-defined standard reduces analytical uncertainty and increases confidence in comparisons between batches, development samples and the reference product.
2: Why Is Reference Standard Development Important for Biosimilars?
Reference standard development is important because biosimilar quality assessments depend on reliable comparisons against appropriate reference materials. If a standard is poorly characterized, unstable or unsuitable for its intended use, the resulting data become difficult to interpret.
1. Establishing a Reliable Analytical Baseline
A reference standard provides a defined baseline for comparing samples. This is especially important when investigating subtle differences in structure, purity, charge distribution, glycosylation or aggregation.
2. Supporting Analytical Similarity and the Comparability Exercise
Biosimilar development involves a comprehensive comparison of the proposed biosimilar with the reference product. Appropriate reference materials let laboratories assess physicochemical and functional attributes with validated or suitably qualified procedures. This analytical foundation also underpins any comparability exercise in biosimilar development, whether it follows a process change or supports a similarity claim.
3. Improving Batch-to-Batch Consistency
A qualified in-house standard supports routine monitoring of manufacturing consistency. Comparing production batches with an established profile helps identify unexpected variation and investigate process-related changes.
4. Supporting Stability and Degradation Studies
Reference materials are used in stability-indicating methods, degradation investigations and analytical controls. Their own stability must be understood, because changes in the standard can compromise the interpretation of sample results.
5. Strengthening Quality and Regulatory Documentation
Documented qualification shows how materials were selected, characterized, stored, monitored and approved. This supports data traceability and gives reviewers a clearer scientific basis for conclusions.
Business value
- Lower risk of failed or repeated studies
- Reliable batch disposition decisions
- Smoother technology transfer between sites
- Audit-ready documentation at every stage
3: How Is a Biosimilar Reference Standard Developed and Characterized?
A reference standard is developed through a predefined, documented workflow based on the molecule, intended use, available material and the risk attached to each critical quality attribute.
| Development stage | Main activities | Expected outcome |
|---|---|---|
| Define intended use | Identify analytical applications and quality requirements | Reference standard qualification plan |
| Select material | Evaluate source, lot history, handling and suitability | Appropriate candidate material |
| Establish baseline | Record initial analytical profile and sample condition | Baseline characterization dataset |
| Perform characterization | Apply orthogonal structural, purity and functional methods | Comprehensive quality profile |
| Assess homogeneity | Investigate variation between containers or aliquots | Evidence of material consistency |
| Evaluate stability | Assess storage, handling and potential degradation | Supported storage and use conditions |
| Qualify and document | Review results, acceptance criteria, deviations and limitations | Approved reference standard documentation |
| Monitor lifecycle | Reassess performance and manage replacement or requalification | Continued suitability for intended use |
Step 1: Define the Intended Use
First establish whether the material will be used for identity testing, quantitative analysis, potency assessment, system suitability, characterization or routine quality control. Intended use sets the depth of characterization. A material used for peptide mapping needs well-established identity and peptide coverage, whereas a standard used for potency testing also needs a suitable functional qualification strategy.
Step 2: Select and Assess the Candidate Material
Candidates are assessed for source, provenance, lot information, storage history, documentation and suitability. Where an approved reference product is used, handling should follow the product information and study protocol. Where an in-house standard is developed, its preparation, representativeness and relationship to the material it controls should be scientifically justified.
Step 3: Perform Biosimilar Reference Standard Characterization
Initial characterization establishes the baseline profile before routine use. It may include identity, purity, aggregation, charge variants, glycosylation, relevant structural attributes and biological activity. Not every test is needed for every molecule, so a risk-based strategy selects methods according to the product’s characteristics and the standard’s purpose.
Step 4: Evaluate Homogeneity and Stability
Homogeneity assessment checks that the material is consistent across containers or aliquots. Stability assessment evaluates whether storage, transport, handling and repeated use could change the attributes the standard is needed for. The evidence supports storage conditions, handling instructions, monitoring intervals and decisions on requalification or replacement.
Step 5: Assign Attributes and Qualify Working Standards
Results are consolidated into a defined profile with justified ranges and criteria. Secondary standards are then qualified against the primary standard so routine testing stays linked to the benchmark.
Step 6: Approve and Control the Reference Standard
The final package documents identity, results, acceptance criteria, limitations, storage conditions, handling instructions and approval status. Change control should address replacement lots, revised methods, unexpected trends and changes in intended use.
Method fitness and validation
Characterization is only as reliable as its methods. Methods are developed or verified for their intended purpose, with attention to specificity, accuracy, precision and robustness in line with ICH Q2(R2) and ICH Q14 principles.
4: Which Analytical Techniques Are Used in Biosimilar Reference Standard Characterization?
The core techniques are high-resolution mass spectrometry, chromatography, capillary electrophoresis, light-scattering and spectroscopic methods, and functional assays, used together as an orthogonal panel.
| Attribute group | Typical techniques | What they show |
|---|---|---|
| Primary structure | Intact mass, peptide mapping LC-MS/MS | Sequence, mass accuracy, modifications |
| Post-translational modifications | LC-MS/MS, subunit mass analysis | Oxidation, deamidation, glycation, C-terminal lysine |
| Glycosylation | HILIC-FLD with MS, glycopeptide analysis | Glycan profile, afucosylation, high mannose, sialylation |
| Charge variants | icIEF, cation-exchange chromatography | Acidic and basic species |
| Size variants | SEC-MALS, CE-SDS, AUC | Monomer, aggregates, fragments |
| Higher-order structure | CD, FTIR, fluorescence, DSC, HDX-MS | Folding and thermal stability |
| Purity and impurities | RP-HPLC, HCP and residual DNA assays | Product- and process-related impurities |
| Biological activity | Cell-based potency, SPR, ELISA | Function and target binding |
Why orthogonal methods matter
A single method can miss a variant. Techniques based on different physical principles confirm each finding independently and show regulators the conclusions are robust.
5: Which Quality Attributes Must Biosimilar Reference Standard Characterization Cover?
Characterization must cover every attribute that could affect safety, efficacy, immunogenicity or pharmacokinetics, ranked by criticality so testing depth follows risk.
| Critical quality attribute | Why it matters | Risk area |
|---|---|---|
| Amino acid sequence and mass | Confirms identity versus the reference product | Efficacy, safety |
| Glycan profile | Influences effector function, half-life, immunogenicity | Efficacy, PK, immunogenicity |
| Charge heterogeneity | Can alter binding, stability, clearance | Efficacy, stability |
| Aggregates and fragments | Linked to immunogenicity risk | Safety |
| Oxidation/deamidation in CDRs | May reduce binding and potency | Efficacy |
| Higher-order structure | Correct folding is needed for function | Efficacy, stability |
| Potency and binding | Demonstrates the intended mechanism | Efficacy |
| Process-related impurities | HCP and DNA can affect safety | Safety |
Functional attributes and bioassays
Structural data alone do not prove a standard behaves like the product. A well-designed biosimilar functional bioassay development service links structural attributes to mechanism-relevant activity, which is essential when a standard is used for potency testing.
Immunogenicity-related attributes
Aggregates, glycan variants and certain modifications can influence immune response. Characterization data feed directly into immunogenicity assessment in biosimilar development, helping teams decide which attributes warrant closer evaluation.
6: How Does Reference Standard Data Connect to Clinical and Regulatory Strategy?
Strong characterization data reduce uncertainty, and the less uncertainty remains, the more targeted the clinical program can be. This is why analytical work and clinical planning should be designed together.
- PK/PD studies: Analytical similarity sets the context for the role of PK/PD studies in biosimilar development, where exposure and response are compared between the biosimilar and reference product.
- Biomarkers: Where suitable, pharmacodynamic biomarkers in biosimilar development can provide sensitive evidence of similar biological effect.
- Evolving regulatory thinking: The EMA reflection paper on a tailored clinical approach reflects growing interest in relying more on analytical and functional evidence. Sponsors should confirm the current status of this guidance before finalizing a plan.
- Remaining gaps: Even strong packages can leave questions. Understanding and addressing residual uncertainty in biosimilar development is part of a credible, risk-based strategy.
Do Storage and Container Closure Affect Reference Standards?
Yes. Contact with container closure components can introduce leachables or alter a standard over time, which can undermine its stability and the reliability of data generated with it. Evaluating packaging early, including extractables and leachables (E&L) testing for biosimilar drug development, helps protect the integrity of both the product and the standards used to control it.
What Regulatory Guidelines Govern Biosimilar Reference Standard Characterization?
No single document covers everything, but ICH quality guidelines together with FDA, EMA, WHO and Health Canada biosimilar guidance expect a thorough, science-based analytical comparison supported by validated or suitably qualified methods.
| Authority | Relevant guidance | Relevance |
|---|---|---|
| ICH | Q6B, Q5E, Q2(R2), Q14, Q5C | Specifications, comparability, method suitability, stability |
| US FDA | Guidance on scientific and quality considerations in demonstrating biosimilarity | Totality of evidence, analytical similarity |
| EMA | Guideline on similar biological medicinal products, quality issues | EU quality comparability |
| WHO | Guidelines on evaluation of biosimilars | Global baseline |
| Health Canada | Requirements for biosimilar biologic drugs | Canadian submissions |
Guidance evolves, so sponsors should confirm the current version with each authority. Our team tracks updates so characterization strategy stays aligned with target markets.
Why Choose ResolveMass for Biosimilar Reference Standard Characterization?
ResolveMass Laboratories Inc. is a Canadian analytical CRO/CDMO specializing in biosimilar characterization and mass spectrometry, which makes it a practical partner for developers who need defensible reference standard data.
| What sponsors need | How ResolveMass addresses it |
|---|---|
| Specialist expertise | Focus on biosimilar characterization, mass spectrometry, PLGA-based drug delivery and nitrosamine testing |
| Method depth | Orthogonal panels built on high-resolution MS, chromatography, electrophoresis and functional assays |
| Regulatory alignment | Study design referencing ICH, FDA, EMA, WHO and Health Canada expectations |
| Data integrity | Documented procedures and review of raw data behind every reported value |
| Clear communication | Defined deliverables and direct access to the scientists on your project |
| Confidentiality | Sponsor data and materials handled under confidentiality agreements |
We encourage sponsors to request method summaries, example report structures and the qualifications of assigned scientists. Open, checkable detail is the best test of any analytical partner.
What Are the Common Challenges?
| Challenge | Practical approach |
|---|---|
| Limited or variable reference product lots | Source multiple lots early and document lot history and expiry |
| Complex glycan and charge heterogeneity | Combine MS with chromatographic and electrophoretic profiling |
| Low-abundance variants | Use high-sensitivity HRMS with orthogonal confirmation |
| Method transfer between sites | Define system suitability and acceptance criteria beforehand |
| Standard depletion and aging | Plan working-standard qualification and requalification up front |
| Shifting regulatory expectations | Confirm current guidance during planning |
Conclusion:
Biosimilar Reference Standard Characterization gives every later result a trustworthy anchor, strengthens comparability arguments and reduces regulatory friction. Done well, it combines orthogonal analytics, risk-based attribute selection, clear documentation and a lifecycle plan for the standard.
Frequently Asked Questions:
No. Reference standard characterization establishes the material’s analytical properties and suitability for its intended use. Biosimilarity requires a broader, product-specific assessment of comparative analytical and functional evidence and other evidence applicable to the regulatory pathway.
Stability is evaluated by monitoring relevant quality attributes under defined storage and handling conditions over time. The results help establish appropriate storage conditions, handling instructions, monitoring intervals, and criteria for requalification or replacement.
Glycosylation analysis helps identify and compare glycan profiles that may influence biological activity, pharmacokinetics, stability, or other product characteristics. Its importance depends on the structure and mechanism of action of the biological product.
A reference product is the approved biological medicine used as the comparator in biosimilar development under the applicable regulatory framework. An in-house reference standard is a material qualified for specific internal analytical applications and controlled through documented procedures.
Not necessarily. A reference standard may be suitable for some applications but not others. Its suitability depends on its qualification, assigned properties, intended use, and the performance requirements of each analytical method.
A qualification report generally includes material identification and history, intended use, analytical methods, results, acceptance criteria, deviations, stability findings, storage conditions, limitations, and approval records.
Reference
- Ahmad AS, Olech E, McClellan JE, Kirchhoff CF. Development of biosimilars. InSeminars in arthritis and rheumatism 2016 Apr 1 (Vol. 45, No. 5, pp. S11-S18). WB Saunders.https://www.sciencedirect.com/science/article/pii/S0049017216000287
- Rahalkar H, Cetintas HC, Salek S. Quality, non-clinical and clinical considerations for biosimilar monoclonal antibody development: EU, WHO, USA, Canada, and BRICS-TM regulatory guidelines. Frontiers in Pharmacology. 2018 Sep 28;9:1079.https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2018.01079/full
- Lee JH, Paek K, Moon JH, Ham S, Song J, Kim S. Biological Characterization of SB3, a Trastuzumab Biosimilar, and the Influence of Changes in Reference Product Characteristics on the Similarity Assessment: JH Lee et al. BioDrugs. 2019 Aug 1;33(4):411-22.https://link.springer.com/article/10.1007/s40259-019-00362-5
- Kirchhoff CF, Wang XZ, Conlon HD, Anderson S, Ryan AM, Bose A. Biosimilars: key regulatory considerations and similarity assessment tools. Biotechnology and bioengineering. 2017 Dec;114(12):2696-705.https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/abs/10.1002/bit.26438
- Mascarenhas-Melo F, Diaz M, Gonçalves MB, Vieira P, Bell V, Viana S, Nunes S, Paiva-Santos AC, Veiga F. An overview of biosimilars—development, quality, regulatory issues, and management in healthcare. Pharmaceuticals. 2024 Feb 11;17(2):235.https://www.mdpi.com/1424-8247/17/2/235
- Nupur N, Chhabra N, Dash R, Rathore AS. Assessment of structural and functional similarity of biosimilar products: rituximab as a case study. InMAbs 2018 Jan 2 (Vol. 10, No. 1, pp. 143-158). Taylor & Francis.https://www.tandfonline.com/doi/abs/10.1080/19420862.2017.1402996
About the Author
